Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Unknown1
Not Yet Recruiting1
Active Not Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07172256Phase 2Not Yet Recruiting

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

NCT06169280Phase 1Recruiting

Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma

NCT04096066Phase 3Active Not Recruiting

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

NCT05712083Phase 2Unknown

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Showing all 4 trials

Research Network

Activity Timeline